RE:RE:RE:RE:RE:RE:RE:WE ARE ALMOST THERE....I believe it was Q2 2015 that we only traded a few molecules for a few weeks and only in a province or two since we haden't received many provincial approvals at that time. Q3 wasn't much better. My estimates are very conservative and I believe realistic since we will have added costs of sales staff. If we keep our expectations realistic than there is less chance of being disappointed when we do get results. Either way if we achieve 5-6 million in sales for 2016, that's a very impressive ramp up, considering how the Canadian economy has been lately. Also my estimates take into effect of what we know now but as Swithwicks mentioned their is huge further potential for even more surprises.
Biosyent has a new investors presentation that sheds light on how well their inferior iron supplement is selling. It's worth a read and sheds light of the potential for this one drug. I just had a quick glance at it but you get the idea: https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnxiaW9zeWVudHxneDoxYjA3MzgzYzdjNDM5NWM5